PBAC's latest decision on Epoprostenol sodium: Recommended with restriction (2011). Considered for second-line therapy for WHO functional class III pulmonary arterial hypertension (PAH) secondary to connective tissue disease and first line therapy for WHO functional class IV PAH secondary to connective tissue disease.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2006
Submissions
2
2006 → 2011
Eligible population
adults with WHO functional class III or IV PAH secondary to connective tissue disease
Therapy area
Respiratory
Line of therapy
Second-line | First-line
Evidence base
RCT, Single-arm
Primary endpoint
6-MWD, haemodynamic parameters
Key trials
VA1A4001, ME97218, Denton (2006)
Comparator
iloprost and bosentan
Economic model
Cost-minimisation
ICER note
Cost minimisation analysis conducted; no ICER calculated by design
Submission history
Mar 2006: Recommended with restriction · Authority Required
Nov 2011: Recommended with restriction · Authority Required